• 1. Rh(iii)-catalyzed chemoselective C–H functionalizations of tertiary aniline N-oxides with alkynes
  Xiaolei Huang,Wenbo Liang,Yang Shi,Jingsong You Chem. Commun. 2016 52 6253
• 2. Nickel-catalyzed cross-coupling of aryltrimethylammonium triflates and amines
  Xue-Qi Zhang,Zhong-Xia Wang Org. Biomol. Chem. 2014 12 1448
• 3. The photosensitised oxidation of amines. Part I. The use of benzophenone as a sensitiser
  R. F. Bartholomew,R. S. Davidson J. Chem. Soc. C 1971 2342
• 4. Endergonic addition of N-methylamines to aromatic ketones driven by photochemical offset of the entropic cost
  Takahiro Iwamoto,Atsushi Hosokawa,Masaharu Nakamura Chem. Commun. 2019 55 11683
• 5. Solvent-controlled chemoselective N-dealkylation-N-nitrosation or C-nitration of N-alkyl anilines with tert-butyl nitrite
  Xuanhua Guo,Chengdong Lv,Qaiser Mahmood,Li Zhou,Guangqiang Xu,Qinggang Wang Org. Chem. Front. 2019 6 3401

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylbenzamines
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylmethylamines Phenylbenzamines
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides

Recent Advances in the Study of N-Benzyl-N-methylaniline (CAS: 614-30-2) in Chemical Biology and Pharmaceutical Research

N-Benzyl-N-methylaniline (CAS: 614-30-2) is an organic compound that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound, characterized by its benzyl and methyl substituents on the nitrogen atom of aniline, serves as a key intermediate in the synthesis of various pharmacologically active molecules. Recent studies have explored its role in drug discovery, particularly in the development of novel therapeutic agents targeting neurological disorders, cancer, and infectious diseases.

One of the most notable advancements in the study of N-Benzyl-N-methylaniline is its application in the design of small-molecule inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of N-Benzyl-N-methylaniline exhibit potent inhibitory activity against specific kinases involved in cancer cell proliferation. The researchers utilized structure-activity relationship (SAR) analysis to optimize the compound's efficacy, leading to the identification of a lead candidate with promising preclinical results. This study underscores the potential of N-Benzyl-N-methylaniline as a scaffold for developing targeted cancer therapies.

In addition to its role in oncology, N-Benzyl-N-methylaniline has been investigated for its neuroprotective properties. A recent publication in ACS Chemical Neuroscience highlighted the compound's ability to modulate neurotransmitter systems, particularly those involving dopamine and serotonin. The study employed in vitro and in vivo models to elucidate the mechanism of action, revealing that N-Benzyl-N-methylaniline derivatives could mitigate oxidative stress and neuronal apoptosis. These findings suggest potential applications in treating neurodegenerative diseases such as Parkinson's and Alzheimer's.

Another area of interest is the use of N-Benzyl-N-methylaniline in antimicrobial drug development. A 2022 study in Bioorganic & Medicinal Chemistry Letters reported that certain analogs of the compound exhibit broad-spectrum activity against drug-resistant bacterial strains. The researchers attributed this activity to the compound's ability to disrupt bacterial cell membrane integrity and inhibit essential enzymatic processes. This research opens new avenues for addressing the global challenge of antibiotic resistance.

Despite these promising developments, challenges remain in the clinical translation of N-Benzyl-N-methylaniline-based therapeutics. Issues such as bioavailability, metabolic stability, and toxicity profiles need to be addressed through further optimization and preclinical testing. Collaborative efforts between academic institutions and pharmaceutical companies are essential to overcome these hurdles and bring these innovations to market.

In conclusion, N-Benzyl-N-methylaniline (CAS: 614-30-2) represents a valuable scaffold in chemical biology and pharmaceutical research. Its diverse applications in drug discovery, from oncology to neurology and infectious diseases, highlight its potential as a versatile building block for next-generation therapeutics. Continued research and development efforts will be crucial to unlocking its full potential and addressing unmet medical needs.

• 23145-45-1(Benzenemethanaminium, N,N-dimethyl-N-phenyl-, bromide)
• 69267-39-6(Benzenemethanamine, N-methyl-N-(4-methylphenyl)-)
• 3204-68-0(Benzyldimethylanilinium Chloride)
• 97788-15-3(Benzenemethanaminium, N,N-dimethyl-N-(4-methylphenyl)-, bromide)
• 90097-08-8(Benzenemethanamine, N-methyl-N-phenyl-, hydrochloride)
• 101663-45-0(Benzenemethanamine, N-methyl-N-(3-methylphenyl)-)
• 606-87-1(N-Benzyl-N-phenylaniline)
• 91-73-6(N,N-Dibenzylaniline)
• 13456-78-5(N1,N1,N4,N4-Tetrabenzylbenzene-1,4-diamine)
• 103426-99-9(1,4-Benzenediamine, N,N-bis[(4-aminophenyl)methyl]-)